Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be achieved in the tumor, compared to healthy body tissue, are advantageous for the compounds according to the invention.
1. A radiohalogenated benzamide compound of formula (I),
in which
X 1 to X 5 are, each independently of one another, halogen, hydrogen, —NR 1 R 2 , —O—R 3 , a branched or unbranched C 1 -C 10 alkyl group, a branched or unbranched C 2 -C 10 alkenyl group or an aryl or heteroaryl group that is optionally substituted by halogen or alkoxy, wherein two adjacent radicals X 1 to X 5 can form a 5- to 7-membered ring, wherein one or more carbon atoms of the ring can be replaced by heteroatoms,
X 6 is an oxygen or NH,
X 7 and X 8 can be the same or different and are hydrogen, C 1-12 alkyl, C 2-12 alkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 2-6 carbalkoxyalkyl, C 2-6 carbalkoxyalkenyl, C 6-12 aryl or C 6-12 heteroaryl; in each case optionally substituted in one or more places by OR 4 , COOR 5 , CONR 6 R 7 , cyano, halogen or NR 8 R 9 , or
X 7 and X 8 together form a 5- to 7-membered ring, wherein one or more carbons of the ring can be replaced by heteroatoms,
R 1 and R 2 are the same or different and are hydrogen, C 1-12 alkyl, C 2-12 alkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 2-6 carboxyalkyl, C 2-6 carboxyalkenyl, C 1-12 alkyl, C 6-12 arylsulfonyl, carboxyaryl, in particular C 7-13 carboxyaryl, carboxy heteroaryl; in each case optionally substituted in one or more places by aryl, heteroaryl, OR 4 , COOR 5 , CONR 6 R 7 , cyano, halogen or NR 8 R 9 , or two substituents taken together form a 3, 4, 5, 6, 7 or 8 membered ring, optionally with 1, 2, 3, or 4 hetero atoms, provided that R 1 and R 2 cannot simultaneously be hydrogen,
R 3 is hydrogen, C 6-12 aryl, heteroaryl, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkinyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, in each case optionally substituted in one or more places by OR 4 , COOR 5 , CONR 6 R 7 , cyano, halogen or NR 8 R 9 ,
R 4 and R 5 are the same or different and are hydrogen, C 1-12 alky, C 2-12 alkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, optionally substituted in one or more places by aryl, heteroaryl, OR 10 , COOR 11 , CONR 6 R 7 , cyano, halogen or NR 8 R 9 ,
R 6 , R 7 ,
R 8 and R 9 are the same or different and are hydrogen, C 1-12 alkyl, C 2-12 alkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, in each case optionally substituted in one or more places by OR 4 , or
R 6 and R 7 or
R 8 and R 9 in each case together form a 5- to 7-membered ring, wherein one or more carbons of the ring can be replaced by heteroatoms, and
R 10 , R 11 are the same or different and are hydrogen, C 1-12 alkyl, C 2-12 alkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, which are optionally substituted in each case in one or more places by aryl, heteroaryl, OR 4 , COOR 5 , CONR 6 R 7 , cyano, halogen, or NR 8 R 9 ,
provided that
at least one of radicals X 1 to X 5 is a radioactive halogen,
at least one of radicals X 1 to X 5 is —O—R 3 ,
at least one of radicals X 1 to X 5 is a radical of formula —NR 1 R 2 , in which either R 1 or R 2 is a substituted or unsubstituted carboxyalkyl, carboxyalkenyl carboxyaryl or carboxyheteroaryl, and
if X 1 is methoxy, X 6 is O, X 8 is hydrogen, X 7 is NH(CH 2 ) 2 NEt 2 , and X 4 means I 131 , X 3 is not NHAc,
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 , wherein the radioactive halogen is F-18, Br-75, I-123, I-124, I-125, I-131 or At-211.
3. A compound according to claim 2 , wherein the radioactive halogen is [I-131], whose specific activity is 10 mCi/mg to 1500 mCi/mg.
4. A compound according to claim 1 , wherein X 6 is oxygen.
5. A compound according to claim 1 , wherein X 6 is NH.
6. A compound according to claim 1 , wherein one of X 7 and X 8 is hydrogen.
7. A compound according to claim 1 , wherein one of X 7 and X 8 is hydrogen, while the other X 7 or X 8 is C 1 -C 12 alkyl, substituted with an amine —NR 8 R 9 .
8. A compound according to claim 7 , wherein the other X 7 or X 8 is C 2 , C 3 or C 4 alkyl, substituted with an amine —NR 8 R 9 .
9. A compound according to claim 8 , wherein R 8 and R 9 are C 2 H 5 or form a 5- or 6-membered ring, wherein one or more carbon atoms of the ring can be replaced by heteroatoms.
10. A compound according to claim 1 , wherein one of radicals X 1 to X 5 —NR 1 R 2 .
11. A compound according to claim 10 , wherein R 1 is carboxyaryl group, and R 2 is hydrogen.
12. A compound according to claim 10 , wherein R 1 is a unsubstituted or substituted C 2 -C 6 carboxyalkyl, C 2 -C 6 carboxyalkenyl, C 7-13 carboxyaryl or C 7-13 carboxyheteroaryl and R 2 is hydrogen.
13. A compound according to claim 1 , wherein X 1 is —O—CH 3 , —O—C 2 H 5 , —O—C 2 H 5 —O—CH 3 or —O—C 2 H 5 —OH.
14. A compound according to claim 1 , wherein X 1 is an —O—CH 3 , X 4 is [123]iodine, [125]iodine, or [131]iodine, and X 3 is —NR 1 R 2 , in which R 1 is a substituted or unsubstituted carboxyaryl group, and R 2 is hydrogen.
15. A compound according to claim 14 , wherein R 1 is C 7 carboxyaryl, optionally substituted with one or more halogen, —O—R 4 or two substitutents taken together form a 3, 4, 5, 6, 7 or 8 membered ring, optionally with 1, 2, 3 or 4 hetero atoms.
16. A compound according to claim 15 , in which R 1 is a benzo[1,3]dioxole-5-carboxylic acid group, benzo-carboxylic acid group, 1-chloro-benzo-4-carboxylic acid group, 1-fluoro-benzo-4-carboxylic acid group, or 1-methoxy-benzo-4-carboxylic acid group and R 2 is hydrogen.
17. A compound according to claim 1 , wherein X 1 is —O—C 2 H 5 , X 4 is [123]iodine, [125]iodine or [131] iodine, and X 3 is —NR 1 R 2 , in which R 1 is a benzo[1,3]dioxole-5-carboxylic acid group, benzo-carboxylic acid group, 1-chloro-benzo-4-carboxylic acid group, 1-fluoro-benzo-4-carboxylic acid group, or 1-methoxy-benzo-4-carboxylic acid group and R 2 is hydrogen.
18. A compound according to claim 1 , wherein X 1 is —O—C 2 H 5 —O—CH 3 , X 4 is [123]iodine, [125]iodine or [131]iodine, and X 3 is —NR 1 R 2 , in which R 1 is a benzo[1,3]dioxole-5-carboxylic acid group, benzo-carboxylic acid group, 1-chloro-benzo-4-carboxylic acid group, 1-fluoro-benzo-4-carboxylic acid group, or 1-methoxy-benzo-4-carboxylic acid group and R 2 is hydrogen.
19. A compound according to claim 1 , wherein X 1 is —O—C 2 H 5 —OH, X 4 is [123]iodine, [125]iodine or [131]iodine, and X 3 is —NR 1 R 2 , in which R 1 is a benzo[1,3]dioxole-5-carboxylic acid group, benzo-carboxylic acid group, 1-chloro-benzo-4-carboxylic acid group, 1-fluoro-benzo-4-carboxylic acid group, or 1-methoxy-benzo-4-carboxylic acid group and R 2 is hydrogen.
20. A compound according to claim 1 , wherein at least one of X 1 to X 5 is —NR 1 R 2 , wherein R 1 is a carboxyaryl group, and R 2 is hydrogen, and one of X 1 to X 5 is —O—R 3 , X 6 is NH, and one of X 1 to X 5 is a [123]iodine, [125]iodine or [131]iodine.
21. A compound according to claim 1 , wherein at least one of X 1 to X 5 is —NR 1 R 2 , wherein R 2 is a carboxyaryl group, and R 3 is hydrogen, and one of X 1 to X 5 is —O—CH 3 , X 6 is NH, and one of X 1 to X 5 is [123]iodine, [125]iodine or [131]iodine.
22. A process for preparing a pharmaceutical composition comprising mixing a compound according to claim 1 with a pharmaceutically acceptable vehicle.
23. A pharmaceutical composition, comprising a pharmaceutically acceptable vehicle and a compound according to claim 1 , wherein the radioactive halogen is F-18, Br-75, I-123, I-124, I-125, I-131 or At-211.
24. A pharmaceutical composition according to claim 23 , wherein the radioactive halogen is [I-131], whose specific activity is 10 mCi/mg to and 1500 mCi/mg.
25. A method for the diagnosis and/or treatment of a tumor or melanoma, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 .
26. A compound according to claim 15 , which is of formula IIa, IIb IIc, IId or IIe
27. A pharmaceutical composition comprising a pharmaceutically acceptable vehicle and a compound according to claim 1 .
28. A compound according to claim 1 , wherein
X 1 to X 5 are, each independently of one another, halogen, hydrogen, —NR 1 R 2 , an ether of formula —O—R 3 , a branched or unbranched C 1 -C 10 alkyl group, a branched or unbranched C 2 -C 10 alkenyl group or an aryl or heteroaryl group that is optionally substituted by halogen or lower alkoxy, wherein two adjacent radicals X 1 to X 5 can form a 5- to 7-membered ring, wherein one or more carbon atoms of the ring can be replaced by heteroatoms.
29. A compound according to claim 1 , wherein
R 1 and R 2 are the same or different and are hydrogen, C 1-12 alkyl, C 2-12 alkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 2-6 carboxyalkyl, C 2-6 carboxyalkenyl, C 1-12 alkyl, C 6-12 arylsulfonyl, carboxyaryl, in each case optionally substituted in one or more places by aryl, heteroaryl, OR 4 , COOR 5 , CONR 6 R 7 , cyano, halogen or NR 8 R 9 .